Steven A. Weissman

Steven A. Weissman is an experienced executive with a career spanning over 25 years. In 2020, they joined Cognition Therapeutics, Inc. as Executive Director and Head of CMC. From 2015 to 2020, they were Director of Chemical Development at Lexicon Pharmaceuticals, Inc., where they were responsible for commercial manufacturing of telotristat etiprate (Xermelo) drug substance at international CMOs and was the CMC administrator for Veeva document management system. From 2013 to 2015, they were Director of Process Chemistry/QA at J-Star Research, where they provided technical and project leadership to clients for process development and manufacture of clinical trial drug substance. From 2012 to 2013, they were the Principal Consultant and Founder of SAW Consulting LLC. From 2009 to 2012, they were Associate Director of Process Chemistry at Concert Pharmaceuticals, where they were responsible for developing IND-enabling routes to deuterated drug candidates. From 1995 to 2009, they were with Merck where they held two roles: Senior Investigator (Process Research) and Research Fellow/Senior Research Fellow (Manufacturing/Research). In their roles, they directed and conducted the rapid lab development of scalable chemical processes, developed robust new methodologies, and oversaw technology transfer to pilot plant and manufacturing facilities.

Steven A. Weissman obtained a PhD in Chemistry from Tufts University, a mini-MBA in Biopharma Innovation from Rutgers University in 2009, and a BA in Chemistry from the University of Vermont.